Scholars@Duke
Andrew Benjamin Nixon

Andrew Benjamin Nixon

Professor in Medicine
Medicine, Medical Oncology
anixon@duke.edu
Duke Box 2631, Durham, NC 27710
133 Jones, Research Drive, Durham, NC 27710

Scholarly Works - Conferences

Abstract 7735: HER2 expression and tumor-infiltrating lymphocytes predict response to tucatinib plus trastuzumab in HER2 -positive metastatic colorectal cancer (MOUNTAINEER): Exploratory analysis of a multicenter, Phase II trial

Conference Cancer Research · April 3, 2026 AbstractIntroduction:The HER2-targeted doublet, tucatinib and trastuzumab, recently received FDA approval for previously treate ... Full text Cite

Abstract 4802: Evaluation of the circulating angiome in cancer: Translational assessment of a 44-plex angiogenesis biomarker panel

Conference Cancer Research · April 3, 2026 AbstractAngiogenesis, the formation of new blood vessels from existing vasculature, is a hallmark of tumor progression, enabling malignant growth, invasion, and metastasis. Tumor-associated angiogenesis l ... Full text Cite

Abstract 6750: Highly multiplexed immunoassays enable discovery of multimarker EV surface signatures as novel biomarkers

Conference Cancer Research · April 3, 2026 AbstractExtracellular vesicles (EVs) are lipid bilayer particles that mediate cell communication by carrying molecules that reflect their cell of origin. Their enrichment in disease states and accessibili ... Full text Cite

Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.

Conference Journal of Clinical Oncology · February 1, 2022 284 Background: Ramucirumab, a humanized monoclonal antibody targeting VEGFR2, is used for treatment of metastatic gastroesophageal adenocarcinoma after disease progression on first-line chemotherapy. Superior survival outcome is ... Full text Cite

Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.

Conference Journal of Clinical Oncology · May 20, 2021 3568 Background: Diets inducing an elevated insulin response have been associated with increased recurrence and mortality in patients with non-metastatic colorectal cancer, but it remains unknown if postprandial hyperinsulinemia ... Full text Cite

Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).

Conference Journal of Clinical Oncology · February 20, 2021 154 Background: CALGB 90401 was a phase III trial of 1050 pts with mCRPC comparing DP+B versus DP alone. While this trial did not show an improvement in OS in the overall population, there were improved PSA response, objective re ... Full text Cite

Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.

Conference Journal of Clinical Oncology · January 20, 2021 361 Background: Assessment of tumor response in extrapancreatic NETs with metastases can be very challenging. Previous studies suggest a high degree of discordance between local and central imaging reviews, which has implications ... Full text Cite

Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance).

Conference Journal of Clinical Oncology · January 20, 2021 343 Background: Alliance/CALGB 80802, a randomized phase III trial, evaluated sorafenib plus doxorubicin vs. doxorubicin in pts with HCC and showed no improvement in median overall survival (OS) (HR[95CI] 1.05[0.83-1.31]) or PFS ... Full text Cite

Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).

Conference Journal of Clinical Oncology · January 20, 2021 325 Background: Alliance/CALGB 80802 randomized phase III trial evaluated DO+S vs. S in pts with aHCC, and showed no improvement in median OS. Multi-drug resistant pathway mitigation by the Ras/Raf/MEK/ERK pathway Full text Cite

A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.

Conference Cancer Chemother Pharmacol · June 2019 PURPOSE: This study was conducted to define the maximum tolerated dose (MTD), recommended phase two dose (RPTD), and toxicities of gemcitabine + dasatinib (GD) and gemcitabine + dasatinib + cetuximab (GDC) in advanced solid tumor patients. METHODS: This st ... Full text Link to item Cite

Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.

Conference Journal of Clinical Oncology · May 20, 2019 3552 Background: MSI-H cancers are responsive to immune checkpoint blockade (ICB), but nearly half of all patients experience primary or early treatment resistance. Activation of the WNT/B-Catenin pathway can lead to immune exclu ... Full text Cite

Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).

Conference Journal of Clinical Oncology · May 20, 2019 4005 Background: Patients (pts) with progressive advanced well-differentiated neuroendocrine tumors arising outside of the pancreas have limited systemic treatment options. Pazopanib (PZ) is an oral multi-kinase inhibitor with ac ... Full text Cite

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).

Conference Journal of Clinical Oncology · May 20, 2019 e15169 Background: In metastatic colorectal cancer with deficient DNA mismatch repair (dMMR), anti-PD-1 antibody monotherapy produced high tumor response rates and extended progression-free survival compared to lack of benefit fo ... Full text Cite

Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).

Conference Journal of Clinical Oncology · May 20, 2019 3035 Background: Energy balance-associated biomarkers such as insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) have been associated with risk and prognosis of various malignancies. Their relationship to diseas ... Full text Cite

Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).

Conference Journal of Clinical Oncology · May 20, 2019 4083 Background: While gemcitabine plus cisplatin has demonstrated significant antitumor activity as 1st line therapy of BC, there is no effective treatment after failure of gemcitabine-based therapy. REG is ... Full text Cite

Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.

Conference Journal of Clinical Oncology · May 20, 2019 TPS4150 Background: Ramucirumab is used for treatment of metastatic gastroesophageal adenocarcinoma after disease progression on first-line chemotherapy. Superior survival outcome is expected when combined with paclitaxel. Howeve ... Full text Cite

Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.

Conference Journal of Clinical Oncology · February 1, 2019 587 Background: The LCCC1029 trial demonstrated that addition of the multitargeted kinase inhibitor regorafenib (Rego) to FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts) modestly prolonged progression-free survival ... Full text Cite

On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).

Conference Journal of Clinical Oncology · February 1, 2019 588 Background: CALGB/SWOG 80405 found no difference in overall survival (OS) or progression-free survival (PFS) in 1137 patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with either the anti-VEGF agent bev ... Full text Cite

Dynamic Changes in Cell-Free DNA During Chemoradiation for Non–small Cell Lung Cancer

Conference International Journal of Radiation Oncology*Biology*Physics · October 2017 Full text Cite

Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.

Conference Journal of Clinical Oncology · May 20, 2017 11546 Background: TRC105, an endoglin-targeting monoclonal antibody with anti-angiogenic and anti-tumor activity, is being evaluated in multiple diseases. Here we report on pharmacodynamic and prognostic biomarkers in patients (p ... Full text Cite

Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502).

Conference Journal of Clinical Oncology · May 20, 2017 TPS3630 Background: In metastatic colorectal cancer with deficient DNA mismatch repair (MMR), anti-PD-1 antibody monotherapy produced high tumor response rates and extended progression-free survival compared to lack of benefit fo ... Full text Cite

Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).

Conference Journal of Clinical Oncology · May 20, 2017 4522 Background: Elevated baseline HGF levels were associated with shorter OS in pts treated with BEV+INF. We evaluated on-treatment HGF levels to describe treatment-related changes and associations with outcome. Methods: We anal ... Full text Cite

Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.

Conference Journal of Clinical Oncology · May 20, 2017 3528 Background: CALGB 80405 is a phase III clinical trial of FOLFOX and FOLFIRI w/ randomly assigned cetuximab or bevacizumab. Novel machine learning approaches to the study dataset provide valuable insights into CRC prognosis a ... Full text Cite

Abstract 3388: Genetic prediction of VEGF-A plasma levels in cancer patients

Conference Cancer Research · July 15, 2016 AbstractABSTRACTBackground: Angiogenesis is an essential event in tumor growth, progression and metastasis and is strongly regulated by multiple VEGF ligands and receptors. W ... Full text Cite

Phase II trial of dovitinib in recurrent glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2015 Full text Cite

Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).

Conference Journal of Clinical Oncology · January 20, 2015 306 Background: CALGB 80303 evaluated gemcitabine (G) in combination with either B or placebo (P) in 602 patients (pts) with APC. No significant difference in overall survival (OS) between treatment arms was observed. Previously, ... Full text Cite

Abstract 2674: Stroma biology identifies heparins as differentiating agents in neuroblastoma

Conference Cancer Research · October 1, 2014 AbstractThe neuroblastoma tumor stroma is thought to suppress neuroblast growth via release of soluble differentiating factors. Here we identify these factors and design a novel therapy based on their mechan ... Full text Cite

Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).

Conference Journal of Clinical Oncology · January 20, 2014 448 Background: Previously, we identified potential predictive biomarkers of C sensitivity related to EGFR signaling from archived tumor tissue from CALGB 80203. Due to the fact that blood-based markers are more convenient and ca ... Full text Cite

Abstract 5041: The type III TGF-beta receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.

Conference Cancer Research · April 15, 2013 AbstractGrowth factors and their receptors coordinate neuronal differentiation during development, yet their roles in the pediatric tumor neuroblastoma remain unclear. Here we report that expression of type ... Full text Cite

Variation in Microenvironmental Effects and Drug Delivery between Different Classes of Antiangiogenic Drugs

Conference International Journal of Radiation Oncology*Biology*Physics · November 2010 Full text Cite

The targeting of leukocytes by 5-oxo-eicosanoids

Conference FRONTIERS IN BIOACTIVE LIPIDS · January 1, 1996 Link to item Cite